FRANÇOIS RAVENELLE
Former President & Chief Executive Officer, Inversago Pharma
As CEO of Inversago, the leader in the development of next generation CB1 receptor blocker therapies, François played an integral part in the company’s recent acquisition by Novo Nordisk, totaling up to US$1.075 billion, following an aggregated capital raising of US$110M in three financing rounds over only four years.
François has contributed to the biotech and pharmaceutical industry for more than 20 years, a period during which he built a comprehensive set of skills in pharmaceutical and business development, as well as a proven ability to identify strategic assets, assemble and lead teams of experienced drug developers to move products forward to address unmet medical needs.
Prior to Inversago, François focused on drug development in increasing leadership roles, from early-stage development programs to clinical trials, with key contribution to one approved NDA. François holds a PhD in physical chemistry from McGill University.
